MY180581A - A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof - Google Patents

A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Info

Publication number
MY180581A
MY180581A MYPI2013004226A MYPI2013004226A MY180581A MY 180581 A MY180581 A MY 180581A MY PI2013004226 A MYPI2013004226 A MY PI2013004226A MY PI2013004226 A MYPI2013004226 A MY PI2013004226A MY 180581 A MY180581 A MY 180581A
Authority
MY
Malaysia
Prior art keywords
methods
cyclosporine
preparation
crystalline form
crystalline forms
Prior art date
Application number
MYPI2013004226A
Other languages
English (en)
Inventor
Richard S Graham
Anuradha V Gore
Kiomars Karami
Ke Wu
Scott W Smith
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY180581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MY180581A publication Critical patent/MY180581A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MYPI2013004226A 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof MY180581A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490887P 2011-05-27 2011-05-27

Publications (1)

Publication Number Publication Date
MY180581A true MY180581A (en) 2020-12-02

Family

ID=46178866

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013004226A MY180581A (en) 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Country Status (19)

Country Link
US (4) US8772245B2 (https=)
EP (2) EP3521302A1 (https=)
JP (1) JP6163482B2 (https=)
KR (1) KR102079402B1 (https=)
CN (1) CN103649108B (https=)
AR (1) AR086586A1 (https=)
AU (4) AU2012262513B2 (https=)
BR (1) BR112013030554B1 (https=)
CA (1) CA2836946C (https=)
CL (1) CL2013003400A1 (https=)
IL (2) IL229475A0 (https=)
MX (1) MX362271B (https=)
MY (1) MY180581A (https=)
RU (1) RU2602062C2 (https=)
SG (1) SG10201607344UA (https=)
TW (1) TWI554522B (https=)
UA (1) UA113627C2 (https=)
WO (1) WO2012166610A1 (https=)
ZA (1) ZA201308665B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
ES2666191T3 (es) * 2011-11-15 2018-05-03 Allergan, Inc. Un proceso para la cristalización de la forma 2 de la ciclosporina A
RU2630970C2 (ru) * 2011-11-15 2017-09-15 Аллерган, Инк. Автоклавируемые взвеси циклоспорина а формы 2
RU2639393C2 (ru) * 2011-11-15 2017-12-21 Аллерган, Инк. Состав пролонгированного действия циклоспорина формы 2
JP2015519368A (ja) 2012-06-01 2015-07-09 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ類似体
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US10524661B2 (en) * 2013-06-12 2020-01-07 Proactive Live, Inc. Sleep monitoring and stimulation
MY196111A (en) 2014-07-18 2023-03-15 Allergan Inc Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US10443292B2 (en) * 2016-04-25 2019-10-15 Magna Closures, Inc. Non-contact obstacle detection system for motor vehicles
KR102287226B1 (ko) 2017-05-17 2021-08-11 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
WO2021224901A2 (en) * 2021-08-20 2021-11-11 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
EP4585605A1 (en) * 2022-10-20 2025-07-16 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
KR20250160895A (ko) 2023-03-20 2025-11-14 추가이 세이야쿠 가부시키가이샤 고리형 펩타이드의 공결정을 제조하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
CA2686234A1 (en) * 2007-05-04 2008-11-13 Allergan, Inc. Use of cyclosporines in the treatment of patients with intraocular lenses
JP2011508776A (ja) * 2008-01-04 2011-03-17 アルコン ファーマシューティカルズ リミテッド 安定な水性シクロスポリン組成物

Also Published As

Publication number Publication date
CN103649108A (zh) 2014-03-19
UA113627C2 (xx) 2017-02-27
TWI554522B (zh) 2016-10-21
NZ719272A (en) 2017-10-27
EP3521302A1 (en) 2019-08-07
BR112013030554B1 (pt) 2020-12-15
MX2013013855A (es) 2014-02-17
EP2714720A1 (en) 2014-04-09
US20160083432A1 (en) 2016-03-24
IL290158A (en) 2022-03-01
JP6163482B2 (ja) 2017-07-12
SG10201607344UA (en) 2016-10-28
RU2602062C2 (ru) 2016-11-10
AU2012262513A1 (en) 2013-12-12
US8772245B2 (en) 2014-07-08
KR102079402B1 (ko) 2020-02-19
US9206228B2 (en) 2015-12-08
MX362271B (es) 2019-01-10
RU2013155033A (ru) 2015-07-20
US20140315827A1 (en) 2014-10-23
WO2012166610A1 (en) 2012-12-06
US20130023482A1 (en) 2013-01-24
ZA201308665B (en) 2014-07-30
AR086586A1 (es) 2014-01-08
AU2019204192A1 (en) 2019-07-04
BR112013030554A2 (pt) 2016-09-06
EP2714720B1 (en) 2018-12-26
US20210269484A1 (en) 2021-09-02
TW201311730A (zh) 2013-03-16
CA2836946A1 (en) 2012-12-06
AU2017265008A1 (en) 2017-12-07
AU2016203990A1 (en) 2016-06-30
NZ618213A (en) 2016-05-27
JP2014515372A (ja) 2014-06-30
AU2019204192B2 (en) 2021-02-04
CA2836946C (en) 2017-08-01
AU2012262513B2 (en) 2016-03-17
CN103649108B (zh) 2017-03-29
KR20140047054A (ko) 2014-04-21
CL2013003400A1 (es) 2014-08-18
IL229475A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
SG10201906113RA (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
CA2865011C (en) Methods and compositions for treating huntington's disease
NZ708501A (en) Treatment of pulmonary disease
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
WO2013177133A3 (en) Generation of human ips cells by a synthetic self- replicative rna
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
PH12014500904B1 (en) Antibody formulations and methods
MY170713A (en) Treatment protocol of diabetes type 2
SG10202010665YA (en) Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2012106393A3 (en) Withanolide isolated from physalis longifolia and analogs and methods of use thereof
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MY166314A (en) Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations